- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
The Dish: Sampling the Blogs
A quick look at some of the policy-related posts in the science and technology blogosphere:
SEED’s Science and Society blog has posted video of its Science and Society Series with Drew Endy and Annie-Marie Mazaa of the Committee on Science, Technology and Law at the National Academies. The two discuss synthetic biology: the technology behind it, the current state of research, and the legal and regulatory dilemmas it faces.
Expect only one minute of science and environment coverage in five hours of cable news programming, writes Matthew Nisbet at Framing Science. Taking a hard look at the recently released Pew “State of the Media” report, he explores the lack of science coverage on cable news networks.
How to combat the rise of drug-resistant antibiotics? In the wake of a new study indicating that U.S. citizens often fail to complete prescribed courses of antibiotics or use them to treat the wrong kind of infection, 60 Second Science suggests “education, education, education.”
Derek Lowe at In the Pipeline critiques a proposal from MIT professors Stan Finkelstein and Peter Temin for rethinking the drug development process. In their new book, “Resonable Rx: Solving the Drug Price Crisis,” they suggest breaking up the pharmaceutical business into drug discovery firms and drug marketing firms.
Comments on this article
